NYSE$RMD

ResMed Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

ResMed's Q3 2020 results announced, showing revenue growth and increased profitability.

ResMed Inc. reported a 16% increase in revenue to $769.5 million for the third quarter of fiscal year 2020. Non-GAAP operating profit increased by 31%. The company is focused on combating the COVID-19 pandemic through increased ventilator production.

  • Revenue increased by 16% to $769.5 million, or 17% on a constant currency basis.
  • GAAP gross margin was 58.4%, while non-GAAP gross margin expanded 70 bps to 60.0%.
  • Net operating profit increased by 39%, and non-GAAP operating profit rose by 31%.
  • GAAP diluted earnings per share were $1.12, and non-GAAP diluted earnings per share reached $1.29.

Headline financials

Total Revenue

$769M

Previous: $662M+16.2%
EPS (adj)

$1.29

Previous: $0.89+44.9%
Gross margin

58.4%

No prior period
Non-GAAP gross margin

60.0%

No prior period
SG&A expenses percent of revenue

22.4%

No prior period
Capital Expenditures

-$77.4M

Previous: -$46.5M-66.3%
Free Cash Flow

$85.8M

Previous: $58.9M+45.6%
Net Income

$163M

Previous: $105M+54.8%
Operating Income

$218M

Previous: $157M+38.6%
Gross Profit

$450M

Previous: $392M+14.7%
Cash & Equivalents

$353M

Previous: $147M+140.8%
Total Assets

$4.51B

Previous: $4.1B+10.1%
Stock-Based Comp

$14.1M

Previous: $12.8M+9.9%

Revenue & EPS history

ResMed · Revenue · Quarterly

$769M

Q3 2020+16.2%vs Q3 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

ResMed · $963M total across 2 segments · Q1 2024

  • Total Devices
    $565M
  • Total Masks and other
    $398M

Forward guidance

ResMed is confident in its ability to navigate the challenging environment and deliver for all stakeholders, with a strong foundation to accelerate the adoption of digital health solutions.

Tailwinds

  • Operational resilience
  • Strong balance sheet
  • Business continuity plans
  • Growth prospects
  • Ability to serve customers and weather the crisis

Headwinds

  • Challenging clinical environment
  • Challenging economic environment
  • Vigilance required in near term
  • Thoughtful approach needed for business outlook
  • Global COVID-19 pandemic

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.1%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+1.2%

Avg return

30 days after

49%

33 / 67 earnings

Positive

+18.7%

Q3 2024

Best reaction

-19.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-2.9%-2.0%-10.8%
Q2 2026-1.5%+2.1%-0.5%
Q1 2026-1.5%-2.8%+1.4%
Q3 2025+10.1%+10.9%+13.2%
Q2 2025-8.3%-5.8%-9.4%
Q1 2025+7.9%+2.9%+2.7%
Q4 2024+4.9%+2.6%+14.9%
Q3 2024+18.7%+16.4%+16.0%
Q2 2024+6.5%+9.3%+5.2%
Q1 2024-4.2%+0.5%+9.5%
Q4 2023-19.3%-19.3%-28.3%
Q3 2023+7.6%+5.4%-3.8%
Q2 2023-2.8%-1.2%-8.5%
Q1 2023-6.5%-5.6%-1.7%
Q4 2022-1.5%-3.1%-3.1%
Q3 2022-6.9%-8.5%-3.0%
Q2 2022-6.5%+0.5%+6.2%
Q1 2022-1.9%-2.1%-6.3%
Q4 2021+0.5%+0.7%+8.3%
Q3 2021-10.6%-8.6%-2.0%
Q2 2021-5.8%-3.5%-9.9%
Q1 2021+6.2%+12.1%+16.0%
Q4 2020-13.4%-13.6%-14.4%
Q3 2020+1.8%+2.0%+2.9%
Q2 2020-4.1%+0.6%-4.1%
Q1 2020+13.8%+15.7%+14.6%
Q4 2019+1.1%+3.8%+5.4%
Q3 2019+7.9%+7.6%+9.3%
Q2 2019-19.3%-21.5%-13.6%
Q1 2019+6.2%+7.3%+5.7%
Q4 2018-2.1%+0.7%+4.1%
Q3 2018-2.1%-1.4%+6.9%
Q2 2018+13.2%+15.9%+5.1%
Q1 2018+7.7%+7.4%+8.6%
Q4 2017-6.0%-2.6%+0.6%
Q3 2017-5.2%-2.7%-2.3%
Q2 2017+9.5%+7.1%+13.7%
Q1 2017-5.0%-5.3%-8.7%
Q4 2016+5.8%+6.5%+6.0%
Q3 2016-7.4%
Q2 2016+7.1%
Q1 2016+0.1%
Q4 2015+3.6%
Q3 2015-10.3%
Q2 2015+8.6%
Q1 2015+9.5%
Q4 2014-4.1%
Q3 2014-0.4%
Q2 2014-5.7%
Q1 2014-13.2%
Q4 2013+0.5%
Q3 2013+0.9%
Q2 2013+7.0%
Q1 2013-4.7%
Q4 2012+12.8%
Q3 2012+7.6%
Q2 2012+9.7%
Q1 2012-12.0%
Q4 2009-5.4%
Q4 2011-5.4%
Q3 2011-0.9%
Q3 2010-0.9%
Q2 2010+2.2%
Q2 2011+2.2%
Q1 2010+3.6%
Q1 2011+3.6%
Q4 2010+3.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro